Company: ACBM
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0001640334-25-001257
Chunk: 14

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 1
Chunk 14
---
$-          Operating expenses        Selling, general and administrative  10,298   1,483,566 Research and development  -   2,520,000 Total operating expenses  10,298   4,003,566          Loss from operations  (10,298)  (4,003,566)         Other expense        Interest expense - related parties  954   788 Total other expenses  954   788          Loss before income tax expense  (11,252)  (4,004,354)Income tax expense  -   - Net loss $(11,252) $(4,004,354)         Basic and diluted loss per share of common stock $(0.00) $(0.07)         Weighted average number of shares of common stock outstanding  60,042,000   60,042,000 

The accompanying notes are an integral part of these unaudited financial statements.

 5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

(Unaudited)

For the three months ended March 31, 2024

              Additional     Total   Preferred Stock  Common Stock   Paid in   Accumulated  Stockholders'     Shares    Amount    Shares    Amount    Capital    Deficit   Deficit                       Balance, December 31, 2023  -  $-   60,042,000  $60,042  $32,298,442  $(32,615,498) $(257,014)                             Imputed interest on related party loans  -   -   -   -   954   -   954 Net loss  -   -   -   -   -   (11,252)  (11,252)                             Balance, March 31, 2024  -  $-   60,042,000  $60,042  $32,299,396  $(32,626,750) $(267,312)

For the Three months ended March